Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bristol Myers Squibb (BMY)

Bristol Myers Squibb accepts notes in tender offers, with settlement on November 20, 2025

Neutral Impact 3 of 5 financing Written later

Bristol Myers Squibb said holders tendered enough notes by the November 17, 2025 early deadline to exhaust its amended purchase limits, so it will accept all validly tendered Pool 1 notes and most Pool 2 notes and will settle on November 20, 2025. The filing says no later tenders will be accepted, and the company is retiring the purchased notes, which reduces its outstanding debt.

Key points

  • Amended Pool 1 maximum is approximately $3.99 billion, down from $4.0 billion; all validly tendered Pool 1 notes were accepted at 100% proration
  • Amended Pool 2 maximum is approximately $3.51 billion, up from $3.0 billion; notes with priority levels 1 through 4 were accepted in full, and $250 million of the 5.900% notes due 2033 were accepted at a 50.84% proration factor
  • Early Settlement Date is November 20, 2025; the offers were set to expire December 3, 2025, but no final settlement is expected

The filing

CompanyBristol Myers Squibb (BMY)
Form8-K, current report
Filed with the SECNov 18, 2025, 4:41 PM ET
Accession number0001140361-25-042607

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 18, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.